# Transcriptomic Meta-Analysis Identifies Upregulated Clotting and Fibrinolysis Pathways in Colorectal Cancer Tumors Containing Hereditary PMS2 Mismatch Repair Deficiency

**Authors:** Trenton M Gibson, Mauri D Spendlove, Naomi Rapier-Sharman, Brett E Pickett

PMC · DOI: 10.17912/micropub.biology.001159 · 2024-07-27

## TL;DR

This study finds that tumors with hereditary PMS2 deficiency show increased clotting and fibrinolysis activity, which may influence cancer growth and spread.

## Contribution

The study identifies unique transcriptional profiles in PMS2-deficient colorectal tumors, highlighting clotting-related pathways as novel features.

## Key findings

- PMS2-deficient tumors show upregulated prothrombin activation pathways.
- Fibrinolysis and uPA/uPAR signaling are enriched in PMS2-mutated tumors.
- These pathways are linked to tumor invasiveness and metastasis.

## Abstract

Lynch Syndrome is characterized by deficient mismatch repair (dMMR) components. We performed a meta-analysis of multiple RNA-sequencing datasets from patients with different dMMR variants (PMS2, MLH1, and MSH2) to better characterize the unique transcriptional profiles. Our results reveal enriched signaling pathways from tumor samples with germline mutations in the PMS2 gene including upregulation in pathways related to intrinsic and extrinsic prothrombin activation, fibrinolysis, and uPA/uPAR-mediated signaling. These pathways have been associated with tumor growth, invasiveness, and metastasis. This work provides support for further exploration into the role of PMS2 in tumor development, and as a potential therapeutic mechanism.

## Linked entities

- **Genes:** PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395], MLH1 (mutL homolog 1) [NCBI Gene 4292], MSH2 (mutS homolog 2) [NCBI Gene 4436]
- **Diseases:** Lynch Syndrome (MONDO:0005835), colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329] {aka CD87, U-PAR, UPAR, URKR}, PRAP1 (proline rich acidic protein 1) [NCBI Gene 118471] {aka PRO1195, UPA}
- **Diseases:** tumor (MESH:D009369), metastasis (MESH:D009362), Lynch Syndrome (MESH:D003123), Colorectal Cancer Tumors (MESH:D015179)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11320117/full.md

---
Source: https://tomesphere.com/paper/PMC11320117